scispace - formally typeset
P

Philip E. Bourne

Researcher at University of Virginia

Publications -  357
Citations -  64294

Philip E. Bourne is an academic researcher from University of Virginia. The author has contributed to research in topics: Protein Data Bank & Structural genomics. The author has an hindex of 68, co-authored 331 publications receiving 54563 citations. Previous affiliations of Philip E. Bourne include University of Sheffield & University of California, Los Angeles.

Papers
More filters
Journal ArticleDOI

The RCSB Protein Data Bank: new resources for research and education

TL;DR: Improved methods for simple and complex searches of PDB data, creating specialized access to chemical component data and providing domain-based structural alignments enable new opportunities for analyzing and understanding structure data.
Journal ArticleDOI

Immune epitope database analysis resource

TL;DR: The immune epitope database analysis resource (IEDB-AR: http://tools.iedb.org) is a collection of tools for prediction and analysis of molecular targets of T- and B-cell immune responses (i.e. epitopes) and the number of ways in which it can be accessed has been expanded.
Journal ArticleDOI

The RCSB Protein Data Bank: a redesigned query system and relational database based on the mmCIF schema

TL;DR: The Research Collaboratory for Structural Bioinformatics (RCSB) has completely redesigned its resource for the distribution and query of 3D structure data, expanding the functionality of the existing site by providing structure data in greater detail and uniformity, improved query and enhanced analysis tools.
Journal ArticleDOI

The RCSB PDB information portal for structural genomics

TL;DR: The RCSB Protein Data Bank (PDB) offers online tools, summary reports and target information related to the worldwide structural genomics initiatives from its portal at .
Journal ArticleDOI

Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis.

TL;DR: The protocol described in this paper can be included in a drug discovery pipeline in an effort to discover novel drug leads with desired safety profiles, and therefore accelerate the development of new drugs.